Drug Patents owned by Mitsubishi Tanabe

1. Drug name - RADICAVA ORS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241416 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

US10987341 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 12, 2025

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
105MG/5ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in